Breast cancer breakthrough paves a path for further innovatiBNN Bloomberg recently published an article on BriaCell's innovative immunotherapy technology.
Because of immuno-oncology's impressive growth within a relatively short period of time, many biotechnology companies are creating strategic partnerships with larger companies to maximize potential.
BriaCell Therapeutics Corp. (TSXV: BCT) is a biotechnology company that is developing safe and effective immunotherapies for cancer. BriaCell has recently partnered with Incyte Corporation — a company with a rich portfolio of immunotherapies for cancer, described in further detail below. Additionally, the company is currently conducting a Phase I/IIa clinical trial of Bria-IMT™, its lead candidate, in combination with pembrolizumab (KEYTRUDA®); manufactured by Merck & Co., Inc. The Combination Study is listed in clinicaltrials.gov as NCT03328026. Apart from this, BriaCell is developing the first off-the-shelf personalized immunotherapy for advanced stage breast cancer, which is expected to enter the clinic within a year.
BriaCell’s Bria-IMT™ shows incredible potential for cancer treatment
BriaCell’s immunotherapies include Bria-IMT™, a breast cancer cell line engineered to activate the immune system, and Bria-OTS™, BriaCell’s novel off-the-shelf personalized immunotherapy, which works to “awaken” the immune system that has been shut down by the cancer.
Learn more about the company: https://briacell.com/
Read the full article here: https://bit.ly/2wc136F